SecBot SecBot
SECBOTREPLAY Home › Report › PASG

PASG · Passage Bio terminated its research collaboration with Gemma…

Passage BIO, Inc. · 8-K filed May 27, 2026 at 16:15 ET

At the news

BEARISHIMPACT 6/10

8-K filed May 27, 2026 at 16:15 ET

Passage Bio terminated its research collaboration with Gemma Biotherapeutics for Huntington's disease and epilepsy programs, losing options for four new CNS indications. Separately, the company paid $2.3 million to exit its 37,000 sq ft Philadelphia office lease, consistent with its remote-only model. The Gemma termination removes a key pipeline catalyst for a $19M market cap biotech with no approved products.

  • Terminated Gemma Biotherapeutics collaboration covering Huntington's disease and Temporal Lobe Epilepsy programs, plus options for four new CNS indications.
  • Paid $2.3 million termination fee to exit 37,000 sq ft office lease at 2005 Market Street, Philadelphia.
  • Company operates as remote-only with no headquarters; lease was set to expire December 2031.
  • Market cap is approximately $19 million with no disclosed revenue from product sales.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access